Drug Trial Radar · NCT04901195
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
658
Actual
Start
May 27, 2021
Primary completion
Jul 22, 2026
Study completion Jul 22, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- May 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions
- Hidradenitis Suppurativa
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with treatment-emergent adverse events (TEAEs) during the studyTime frame: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)
Locations
145 sites in 19 countries. Site status is shown where the registry gives one.
Hs0005 50140
Birmingham, Alabama
Hs0005 50175
Phoenix, Arizona
Hs0005 50162
Fountain Valley, California
Hs0005 50161
Los Angeles, California
Hs0005 50220
San Diego, California
Hs0005 50196
Thousand Oaks, California
Hs0005 50199
Miami, Florida
Hs0005 50205
North Miami Beach, Florida
Hs0005 50152
Orange Park, Florida
Hs0005 50184
Pembroke Pines, Florida
Hs0005 50193
Sandy Springs, Georgia
Hs0005 50280
Watkinsville, Georgia
Hs0005 50234
Plainfield, Indiana
Hs0005 50425
Murray, Kentucky
Hs0005 50198
Beverly, Massachusetts
Hs0005 50146
Boston, Massachusetts
Hs0005 50178
Clarkston, Michigan
Hs0005 50105
St Louis, Missouri
Hs0005 50194
Omaha, Nebraska
Hs0005 50208
Las Vegas, Nevada
Hs0005 50159
Newington, New Hampshire
Hs0005 50137
East Windsor, New Jersey
Hs0005 50200
Verona, New Jersey
Hs0005 50237
Albuquerque, New Mexico
Hs0005 50235
New York, New York
Hs0005 50151
Chapel Hill, North Carolina
Hs0005 50211
Durham, North Carolina
Hs0005 50179
Winston-Salem, North Carolina
Hs0005 50177
Cincinnati, Ohio
Hs0005 50138
Columbus, Ohio
Hs0005 50145
Columbus, Ohio
Hs0005 50202
Fairborn, Ohio
Hs0005 50204
Tulsa, Oklahoma
Hs0005 50147
Hershey, Pennsylvania
Hs0005 50008
Johnston, Rhode Island
Hs0005 50180
Providence, Rhode Island
Hs0005 50084
Charleston, South Carolina
Hs0005 50236
Greenville, South Carolina
Hs0005 50142
Nashville, Tennessee
Hs0005 50201
Arlington, Texas
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.